基于《中国医疗机构药品评价与遴选指南》对替戈拉生片的评价研究

中国药物评价 ›› 2024, Vol. 41 ›› Issue (2): 160-164.

基于《中国医疗机构药品评价与遴选指南》对替戈拉生片的评价研究

李学峰，高峰丽，张靓靓*

内蒙古科技大学包头医学院第二附属医院，内蒙古包头 014030

收稿日期:2023-12-06 修回日期:2024-03-01 出版日期:2024-04-28 发布日期:2024-04-28

Evaluation Study of Tigorazan Tablets Based on "Rapid Guidelines for Drug Evaluation and Selection in Chinese Medical Institutions"

Department of Pharmacy， the Second Affiliated Hospital of Baotou Medical College， Inner Mongolia University of
Science and Technology， Neimenggu Baotou 014030， China

Received:2023-12-06 Revised:2024-03-01 Online:2024-04-28 Published:2024-04-28
Contact: Zhang LiangLiang

摘要/Abstract

摘要： 目的：对一种新型口服钾离子竞争性酸阻滞剂替戈拉生片进行药品评价，为医疗机构遴选该药品提供参考。方法：使用《中国医疗机构药品评价与遴选指南》（第二版）(以下简称《指南》)的评价维度、评价细则及评价方法，对替戈拉生片进行药品评价。结果：基于《指南》，替戈拉生片的总评分为64.95分。其中，药学特性26分，有效性18分，安全性13分，经济性3.05分，其他4.9分。结论：若医疗机构无替代药品，为弱推荐；有替代药品，则不推荐。《指南》能帮助医疗机构快速地评价与遴选药品，可为医疗机构用药提供指导与参考。

关键词: font-size:medium, ">新型钾离子竞争性酸阻滞剂；替戈拉生；药品评价；药品遴选；中国医疗机构药品评价与遴选指南

Abstract: Objective： A new oral potassium competitive acid blocker， Tigorazantablets， was evaluated to provide reference for medical institutions to select this drug. Methods：The evaluation dimension， evaluation rules and evaluation methods of the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions (second edition) (hereinafter referred to as the " Guide") were used to evaluate Tigorazan tablets. Results：Based on the Guide， the overall rating of Tigorasan tablets was 64.95. Among them， 26 points were scored for pharmaceutical properties， 18 points for effectiveness， 13 points for safety， 3.05 points for economy， and 4.9 points for others. Conclusion：If the medical institution does not have alternative drugs， it is weakly recommended； Alternatives are not recommended. The “Guide” can help medical institutions to evaluate and select drugs quickly， and it can provide guidance and reference for medication use in medical institutions.

Key words: font-size:medium, ">Novel potassium competitive acid blockers； Tegoprazan； Drug evaluation； Drug selection； Rapid guide for drug evaluation and selection in medical institutions in China

中图分类号:

李学峰, 高峰丽, 张靓靓. 基于《中国医疗机构药品评价与遴选指南》对替戈拉生片的评价研究[J]. 中国药物评价, 2024, 41(2): 160-164.

LI Xue-feng, GAO Feng-li, ZHANG Liang-liang. Evaluation Study of Tigorazan Tablets Based on "Rapid Guidelines for Drug Evaluation and Selection in Chinese Medical Institutions"[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2024, 41(2): 160-164.

参考文献

[1] Mermelstein J，Mermelstein AC， Chait MM.Tegoprazan to treat gastroesophageal reflux disease[J].Drugs Today （Barc），2020，56（11）:715 -721.
     [2] Simon WA， Herrmann M，Klein T，et al.Soraprazan: setting new standards in inhibition of gastric acid secretion[J].Pharmacol Exp Ther，2007，321（3）:866 -874.
     [3] Miwa H， Uedo N， Watari J， et al. Randomised clinical trial:efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers-results from two phase 3， non-inferiority randomised controlled trials[J]. Aliment Pharmacol Ther， 2017，45（2）:240-252.
     [4] Han S， Choi HY， Kim YH，et al. Randomised clinical trial:safety， tolerability，pharmacokinetics，and pharmacodynamics of single and multiple oral doses oftegoprazan（CJ-12420），anovel potassium-competitive acid blocker， in healthy male subjects[J].Aliment Pharmacol Ther， 2019， 50（7）:751-759.
     [5] 中华医学会消化病学分会.2020年中国胃食管反流病专家共识[J].中华消化杂志，2020，40(10):649-663.
     [6] 中国医疗保健国际交流促进会胃食管反流多学科分会.中国胃食管反流病多学科诊疗共识[J].中华胃食管反流病电子杂志，2020，7(1):1-28.
     [7] 中华医学会，中华医学会杂志社，中华医学会消化病学分会，等.胃食管反流病基层诊疗指南(2019 年)[J].中华全科医师杂志，2019，18(7):635-641.
     [8] Iwakiri K， Kinoshita Y， Habu Y， et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015[J]. J Gastroenterol，2016，51(8):751-767.
     [9] Hunt R， Armstrong D， Katelaris P， et al. World gastro-enterology organisation global guidelines: GERD global perspective on gastroesophageal reflux disease[J]. J Clin Gastroenterol，2017，51(6):467-478.
     [10] 中华医学会消化病学分会.2020年中国胃食管反流病专家共识[J].中华消化杂志，2020，40(10):649-663.
     [11] Jung HK，Tae CH，Song KH，et al.2020 Seoul Consensus on the diagnosis and management of gastroesophageal reflux disease[J].J Neurogastroenterol Motil，2021，27(4):453-481.
     [12] Zerbib F， Bredenoord AJ， Fass R， et al. ESNM/ ANMS consensus paper:diagnosis and management of refractory gastro-esophageal reflux disease[J].Neurogastroenterol Motil，2021，33(4):e14075.
     [13] Kim SH， Cho KB， Chun HJ， et al..Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment Pharmacol Ther[J]. 2021，54(4):402-411.
     [14] Lee KJ， Son BK， Kim GH，et al. Randomised phase 3 trial: tegoprazan， a novel potassium-competitive acid blocker， vs. esomeprazole in patients with erosive oesophagitis[J]. Aliment Pharmacol Ther，2019，49(7):864-872.
     [15] Cho YK， Choi MG， Choi SC，et al. Randomised clinical trial: tegoprazan， a novel potassium-competitive acid blocker， or lansoprazole in the treatment of gastric ulcer[J]. Aliment Pharmacol Ther，2020，52(5):789-797.
     [16] Cho YK， Kim JH， Kim HS，et al. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis[J]. Aliment Pharmacol Ther， 2023，57(1):72-80.
     [17] Inatomi N， Matsukawa J， Sakurai Y， et al. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases[J]. Pharmacol Ther，2016，168:12-22.
     [18] Takahashi N，Take Y. Tegoprazan， a novel potassium-competitive aci-d blocker to control gastric acid secretion and motility[J].J Pharmacol Exp Ther，2018，364（2）:275 - 286.
     [19] 李正翔，段蓉.国内医疗机构药品遴选评估方法和工具的研究现状及思考[J].中国医院用药评价与分析，2022，22(3):257-260，264.